{"id":"thalidomide-melphalan-prednisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Venous thromboembolism"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL426123","moleculeType":"Small molecule","molecularWeight":"258.23"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Thalidomide enhances T-cell proliferation and IL-2 production while inhibiting TNF-α, melphalan causes DNA crosslinking and cell death in rapidly dividing myeloma cells, and prednisone provides anti-inflammatory and immunosuppressive effects. This triple combination (MPT regimen) is designed to improve response rates and survival in multiple myeloma patients, particularly those ineligible for stem cell transplantation.","oneSentence":"This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:03.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma in patients ineligible for autologous stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":"Multiple Myeloma","enrollment":306},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT01063179","phase":"PHASE3","title":"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":511},{"nctId":"NCT00907452","phase":"NA","title":"Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2009-07-29","conditions":"Myeloma","enrollment":143},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT00232934","phase":"PHASE3","title":"Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients","status":"COMPLETED","sponsor":"Gruppo Italiano per lo Studio del Mieloma Multiplo","startDate":"2002-01","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT00040937","phase":"PHASE2","title":"S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2002-06","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT00406978","phase":"PHASE1, PHASE2","title":"Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Silvio Aime","startDate":"2006-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT00961467","phase":"PHASE2","title":"RMPT for Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2007-02","conditions":"Multiple Myeloma","enrollment":44},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT00218855","phase":"PHASE3","title":"Thalidomide to Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2002-01","conditions":"Multiple Myeloma","enrollment":363},{"nctId":"NCT00205751","phase":"PHASE2, PHASE3","title":"Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy","status":"COMPLETED","sponsor":"Austrian Forum Against Cancer","startDate":"2001-08","conditions":"Multiple Myeloma","enrollment":350},{"nctId":"NCT01532856","phase":"PHASE3","title":"Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years","status":"UNKNOWN","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":64},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00443235","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma More Than 65 Years Old","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2005-03","conditions":"Multiple Myeloma","enrollment":260},{"nctId":"NCT01274403","phase":"PHASE2","title":"A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Gruppo Italiano Studio Linfomi","startDate":"","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00320476","phase":"PHASE2","title":"VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates","status":"COMPLETED","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-04","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT00644306","phase":"PHASE3","title":"Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma","status":"TERMINATED","sponsor":"Central Hospital, Nancy, France","startDate":"2002-04","conditions":"Newly Diagnosed, Multiple Myeloma","enrollment":232},{"nctId":"NCT00358020","phase":"PHASE2","title":"Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2004-11","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT00367185","phase":"PHASE3","title":"Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2000-05","conditions":"Multiple Myeloma","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Thalidomide, Melphalan, Prednisone","genericName":"Thalidomide, Melphalan, Prednisone","companyName":"Grupo de Estudos Multicentricos em Onco-Hematologia","companyId":"grupo-de-estudos-multicentricos-em-onco-hematologia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects. Used for Multiple myeloma in patients ineligible for autologous stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}